Can we disagree without being disagreeable?
@X is in tizzy tirade and mostly against an OPED below by Emma Pierson (
@2plus2make5) and the shaming-cum-silencing, treating her like a cancer -- coming from people in the AI world and/or with MD at the end of their name -- to be eradicated via chemotherapy or resected like a tumour borders on mysoginistic.
It is absolutely disgraceful.
She wrote an OPED.
She is entitled to her opinion.
And I fundamentally disagree with it.
But OMG, the vehement vitriol is sad, wrong, and dangerous.
It is so far removed from passionate debate and the posts from keyboard warriors would never be allowed to stand in daily conversation or what passes for informed debate on a conference platform.
For context, I hate three things in this world: apathy, bigotry, and cancer. Four, if you add pineapples on pizza. 😉
I lost my dad to GBM brain tumour 30 years ago. I live with two pre-cancerous conditions -- closely monitored -- and have helped raise millions for cancer research and clinical trials. I've run, walked, swam, boxed and bled to do this and served local, and now national, foundational research efforts to find cures for various types of cancer.
To be crystal clear: I want to see this disease eradicated from our planet.
Now, Emma Pierson’s recent OPED, “I’d Rather Risk Cancer Than See AI Move This Fast,” raises justifiable concerns about unchecked AI and overhyped timelines for curing cancer(s) which are irresponsibly perpetuated weekly by a cohort of BigTechBros and others who:
- Underestimate the limits of computational biology;
- Believe biology and illness are just a design flaw and complicated engineering issue; and
- Have no comprehension of the rampant regulatory realities of clinical trials design, conduct, Rx drugs/vaccine manufacturing, pharmacovigilance and other biopharma value-chain pursuits.
I share her concern about real risks, but I profoundly disagree with the conclusion that we should broadly slow AI research and progress. Here's why ...
1⃣ This is not a binary choice between “AI cures cancer” and “AI does nothing.” Even if general‑purpose AI does not radically cut cancer mortality in the next decade, current models and systems are already improving target discovery, trial design, imaging, and care pathways in oncology and other diseases.
AI is finding a range of biomarkers and cellular clues that will drive a future of PredictiveAI, PrecisionAI, and PreventiveAI in cancer.
Slowing deployment and research will delay countless, compounding gains that translate into earlier diagnoses, better therapies, and more lives extended. And medicine has always been driven by the Speed of Science!
2⃣ Her article correctly notes that biology is noisy and data are limited, but that is precisely why better tools for pattern‑finding, simulation, and literature synthesis matter ... aka AI!
It is a force‑multiplier for clinicians and researchers, a collaborative and cognitive tool, and its incremental and step-wise innovations across thousands of projects can and WILL add up to a major public‑health impact on cancer's mortality and survivability measures.
3⃣ Risk and speed are NOT the same variable. We can and should aggressively strengthen regulation, safety evaluation, and domain‑specific guardrails -- especially for general‑purpose frontier models -- imposing a blanket brake on medically focused, domain-specific, AI R&D.
In healthcare, the opportunity cost of delay is measured in patient outcomes and lost lives (mothers, fathers, siblings, children, relatives, friends, neighbours, and colleagues) not just in abstract timelines.
💡The real question is not “Would you rather risk cancer or AI?” It is how to maximize the net health benefit of AI while constraining its misuse.
From a health policy and life sciences perspective, the answer looks less like slowing progress, and more like steering it toward validated clinical use cases, rigorous trials, robust oversight, and encouraging and enabling the curiosity of reseaerhers and clinicians to pursue new ideas, faster treatments, and keep patients at centre of care.